OBJECTIVE: Hepatic steatosis is common in HIV-infected individuals. Magnetic resonance spectroscopy (MRS) is the preferred noninvasive method for hepatic steatosis measurement but is expensive. Controlled attenuation parameter (CAP) also assesses hepatic steatosis and is conveniently performed concomitantly with transient elastography. We aimed to assess the accuracy of CAP in the setting of HIV infection. DESIGN: Cross-sectional study. METHODS: CAP and MRS were performed in 82 study participants (39 HIV monoinfected; seven hepatitis C virus (HCV) monoinfected; 21 HIV/HCV coinfected; 15 with neither infection). We used concordance correlation coefficients to compare log-transformed and standardized CAP and MRS values and linear regression to examine factors associated with CAP and MRS-measured hepatic steatosis (MRS-HS). The accuracy of CAP to detect at least mild hepatic steatosis, defined as MRS-liver fat fraction more than 0.05, and the factors associated with discordance between CAP and MRS were evaluated. RESULTS: Overall, CAP-measured hepatic steatosis and MRS-HS correlated moderately well (rc = 0.63; P < 0.001), and correlation was strongest in the HIV-monoinfected group (rc = 0.67; P < 0.001). Body composition factors (higher BMI, waist circumference, visceral and abdominal subcutaneous adipose tissue) and insulin resistance were significantly associated with both greater CAP-measured hepatic steatosis and MRS-HS. Using a validated CAP cut-off of at least 238 dB/m, sensitivity and specificity for at least mild hepatic steatosis were 84% and 75% in the entire cohort; 89% and 80% in the HIV-monoinfected group. Participants with higher body composition parameters were more likely to be misclassified as having hepatic steatosis by CAP. CONCLUSION: Our findings suggest CAP is an acceptable noninvasive surrogate for hepatic steatosis in HIV-infected individuals but may overestimate hepatic steatosis prevalence, especially in individuals with high BMI. Evaluation of factors that improve CAP accuracy and determination of optimal cut-offs are warranted.
OBJECTIVE:Hepatic steatosis is common in HIV-infected individuals. Magnetic resonance spectroscopy (MRS) is the preferred noninvasive method for hepatic steatosis measurement but is expensive. Controlled attenuation parameter (CAP) also assesses hepatic steatosis and is conveniently performed concomitantly with transient elastography. We aimed to assess the accuracy of CAP in the setting of HIV infection. DESIGN: Cross-sectional study. METHODS: CAP and MRS were performed in 82 study participants (39 HIV monoinfected; seven hepatitis C virus (HCV) monoinfected; 21 HIV/HCV coinfected; 15 with neither infection). We used concordance correlation coefficients to compare log-transformed and standardized CAP and MRS values and linear regression to examine factors associated with CAP and MRS-measured hepatic steatosis (MRS-HS). The accuracy of CAP to detect at least mild hepatic steatosis, defined as MRS-liverfat fraction more than 0.05, and the factors associated with discordance between CAP and MRS were evaluated. RESULTS: Overall, CAP-measured hepatic steatosis and MRS-HS correlated moderately well (rc = 0.63; P < 0.001), and correlation was strongest in the HIV-monoinfected group (rc = 0.67; P < 0.001). Body composition factors (higher BMI, waist circumference, visceral and abdominal subcutaneous adipose tissue) and insulin resistance were significantly associated with both greater CAP-measured hepatic steatosis and MRS-HS. Using a validated CAP cut-off of at least 238 dB/m, sensitivity and specificity for at least mild hepatic steatosis were 84% and 75% in the entire cohort; 89% and 80% in the HIV-monoinfected group. Participants with higher body composition parameters were more likely to be misclassified as having hepatic steatosis by CAP. CONCLUSION: Our findings suggest CAP is an acceptable noninvasive surrogate for hepatic steatosis in HIV-infected individuals but may overestimate hepatic steatosis prevalence, especially in individuals with high BMI. Evaluation of factors that improve CAP accuracy and determination of optimal cut-offs are warranted.
Authors: M Sasso; I Tengher-Barna; M Ziol; V Miette; C Fournier; L Sandrin; R Poupon; A-C Cardoso; P Marcellin; C Douvin; V de Ledinghen; J-C Trinchet; M Beaugrand Journal: J Viral Hepat Date: 2011-10-13 Impact factor: 3.728
Authors: Kevin P High; Mark Brennan-Ing; David B Clifford; Mardge H Cohen; Judith Currier; Steven G Deeks; Sherry Deren; Rita B Effros; Kelly Gebo; Jörg J Goronzy; Amy C Justice; Alan Landay; Jules Levin; Paolo G Miotti; Robert J Munk; Heidi Nass; Charles R Rinaldo; Michael G Shlipak; Russell Tracy; Victor Valcour; David E Vance; Jeremy D Walston; Paul Volberding Journal: J Acquir Immune Defic Syndr Date: 2012-07-01 Impact factor: 3.731
Authors: Valentina Li Vecchi; Maurizio Soresi; Lydia Giannitrapani; Paola Di Carlo; Giovanni Mazzola; Pietro Colletti; Antonino Terranova; Giovanni Vizzini; Giuseppe Montalto Journal: Int J Infect Dis Date: 2012-03-17 Impact factor: 3.623
Authors: Jennifer C Price; Yifei Ma; Rebecca Scherzer; Natalie Korn; Kyle Tillinghast; Marion G Peters; Susan M Noworolski; Phyllis C Tien Journal: Hepatology Date: 2017-02-03 Impact factor: 17.425
Authors: Thomas Karlas; David Petroff; Nikita Garnov; Stephan Böhm; Hannelore Tenckhoff; Christian Wittekind; Manfred Wiese; Ingolf Schiefke; Nicolas Linder; Alexander Schaudinn; Harald Busse; Thomas Kahn; Joachim Mössner; Thomas Berg; Michael Tröltzsch; Volker Keim; Johannes Wiegand Journal: PLoS One Date: 2014-03-17 Impact factor: 3.240
Authors: C Busca; M Sánchez-Conde; M Rico; M Rosas; E Valencia; A Moreno; V Moreno; L Martín-Carbonero; S Moreno; I Pérez-Valero; J I Bernardino; J R Arribas; J González; A Olveira; P Castillo; M Abadía; L Guerra; C Mendez; M L Montes Journal: Open Forum Infect Dis Date: 2022-06-09 Impact factor: 4.423
Authors: Veeral H Ajmera; Edward R Cachay; Christian B Ramers; Shirin Bassirian; Seema Singh; Richele Bettencourt; Lisa Richards; Gavin Hamilton; Michael Middleton; Katie Fowler; Claude Sirlin; Rohit Loomba Journal: Clin Infect Dis Date: 2021-06-15 Impact factor: 9.079
Authors: Hugo Perazzo; Sandra W Cardoso; Carolyn Yanavich; Estevão P Nunes; Michelle Morata; Nathalia Gorni; Paula Simplicio da Silva; Claudia Cardoso; Cristiane Almeida; Paula Luz; Valdilea G Veloso; Beatriz Grinsztejn Journal: J Int AIDS Soc Date: 2018-11 Impact factor: 5.396
Authors: Sarah E Sansom; Jonathan Martin; Oluwatoyin Adeyemi; Kerianne Burke; Crystal Winston; Sara Markham; Benjamin Go; Gregory Huhn Journal: Open Forum Infect Dis Date: 2019-03-01 Impact factor: 3.835
Authors: Giovanna Ferraioli; Laura Maiocchi; Maria Vittoria Raciti; Carmine Tinelli; Annalisa De Silvestri; Mara Nichetti; Pasquale De Cata; Mariangela Rondanelli; Luca Chiovato; Fabrizio Calliada; Carlo Filice Journal: Clin Transl Gastroenterol Date: 2019-10 Impact factor: 4.488
Authors: Carmen Busca Arenzana; Lucía Quintana Castanedo; Clara Chiloeches Fernández; Daniel Nieto Rodríguez; Pedro Herranz Pinto; Ana Belén Delgado Hierro; Antonio Olveira Martín; María Luisa Montes Ramírez Journal: Cells Date: 2021-05-04 Impact factor: 6.600